Mr. Christopher J. DelOrefice

Executive Vice President & Chief Financial Officer

Mr. Samrat S. Khichi Esq.

Executive Vice President of Corporation Devel., Public Policy & Regulatory Affairs and Gen. Counsel

Ms. Shana Carol Neal

Executive Vice President & Chief People Officer

Ms. Michelle  Quinn

Executive Vice President & Acting Gen. Counsel

Ms. Elizabeth  McCombs

Executive Vice President & Chief Technology Officer

Ms. Francesca M. DeMartino

Senior Vice President & Head of Investor Relations

Michelle  Quinn

Senior Vice President and Chief Ethics & Compliance Officer

Ms. Denise  Fleming

Executive Vice President of Technology & Global Services and Chief Information Officer

Mr. David B. Hickey

Executive Vice President & Pres of Life Sciences Segment

Mr. Thomas E. Polen Jr.

Pres, Chief Executive Officer & Chairman

Mr. Christopher  DelOrefice

Mr. Thomas J. Spoerel

Senior Vice President, Controller & Chief Accounting Officer

Troy  Kirkpatrick

Vice President of PR

Dr. Joseph M. Smith F.A.C.C, M.D., Ph.D.

Senior Vice President, Chief Scientific Officer & Co-Chair of Scientific Advisory Board

Senior Vice President and Chief Ethics & Compliance Officer and Acting Gen. Counsel

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.

Here are two Dividend Aristocrats that are top-rated Zacks stocks at the moment and can offer unique exposure and diversification to investors' portfolios.

2 Unique Dividend Aristocrats to Diversify the Portfolio

BD's (BDX) receipt of the latest FDA approval is likely to improve the detection and prevention of vaginitis.

BD's (BDX) New FDA Approval to Improve Vaginitis Testing

While it is not the only factor to consider, the annual dividend can solidify whether a stock will benefit you financially. And among the many industry sectors to invest in, healthcare can be one of the most stable, especially regarding the dividend yield.

Healthcare Stocks With at Least 30 Years of Dividend Increases

Some of these companies have been around for over 100 years and have seen all imaginable economic environments

3 Stocks to Buy for Consistent Dividend Growth

Investors continue to be optimistic about BD (BDX) owing to a few regulatory approvals and product launches.

Three Reasons to Add BD (BDX) Stock to Your Portfolio Now

Powered by AI

Becton, Dickinson and Company

240.50